• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病足感染的管理:对澳大拉西亚传染病临床医生的一项调查。

Managing diabetic foot infections: a survey of Australasian infectious diseases clinicians.

作者信息

Commons Robert J, Raby Edward, Athan Eugene, Bhally Hasan, Chen Sharon, Guy Stephen, Ingram Paul R, Lai Katy, Lemoh Chris, Lim Lyn-Li, Manning Laurens, Miyakis Spiros, O'Reilly Mary, Roberts Adam, Sehu Marjoree, Torda Adrienne, Vicaretti Mauro, Lazzarini Peter A

机构信息

1Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, PO Box 41096, Tiwi, Casuarina, Northern Territory Australia.

2Department of Infectious Diseases, Fiona Stanley Hospital, 11 Robin Warren Dr, Murdoch, WA Australia.

出版信息

J Foot Ankle Res. 2018 Apr 10;11:13. doi: 10.1186/s13047-018-0256-3. eCollection 2018.

DOI:
10.1186/s13047-018-0256-3
PMID:29651304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5894166/
Abstract

BACKGROUND

Diabetic foot infections (DFI) present a major morbidity, mortality and economic challenge for the tertiary health sector. However, lack of high quality evidence for specific treatment regimens for patients with DFIs may result in inconsistent management. This study aimed to identify DFI caseload proportion and patterns of clinical practice of Infectious Diseases (ID) Physicians and Trainees within Australia and New Zealand.

METHODS

A cross-sectional online survey of Australian and New Zealand ID Physicians and Trainees was undertaken, to estimate the overall ID caseload devoted to patients with DFIs and assess clinicians' management practices of patients with DFIs.

RESULTS

Approximately 28% (142/499) of ID Physicians and Trainees from Australia and New Zealand responded to the survey. DFI made up 19.2% of all ID consultations. Involvement in multidisciplinary teams (MDT) was common as 77.5% (93/120) of those responding indicated their patients had access to an inpatient or outpatient MDT. Significant heterogeneity of antimicrobial treatments was reported, with 82 unique treatment regimens used by 102 respondents in one scenario and 76 unique treatment regimens used by 101 respondents in the second scenario. The duration of therapy and the choice of antibiotics for microorganisms isolated from superficial swabs also varied widely.

CONCLUSIONS

Patients with DFIs represent a significant proportion of an ID clinician's caseload. This should be reflected in the ID training program. Large heterogeneity in practice between clinicians reflects a lack of evidence from well-designed clinical trials for patients with DFI and highlights the need for management guidelines informed by future trials.

摘要

背景

糖尿病足感染(DFI)对三级医疗部门构成了重大的发病率、死亡率和经济挑战。然而,缺乏针对DFI患者具体治疗方案的高质量证据可能导致管理不一致。本研究旨在确定澳大利亚和新西兰传染病(ID)医生及实习生中DFI病例数的比例以及临床实践模式。

方法

对澳大利亚和新西兰的ID医生及实习生进行了一项横断面在线调查,以估计专门针对DFI患者的ID病例总数,并评估临床医生对DFI患者的管理实践。

结果

来自澳大利亚和新西兰的ID医生及实习生中约28%(142/499)回应了调查。DFI占所有ID会诊的19.2%。参与多学科团队(MDT)很常见,因为77.5%(93/120)的受访者表示他们的患者能够获得住院或门诊MDT服务。报告显示抗菌治疗存在显著异质性,在一种情况下,102名受访者使用了82种独特的治疗方案,在第二种情况下,101名受访者使用了76种独特的治疗方案。从浅表拭子分离出的微生物的治疗持续时间和抗生素选择也有很大差异。

结论

DFI患者占ID临床医生病例总数的很大比例。这一点应在ID培训计划中得到体现。临床医生之间实践的巨大异质性反映出缺乏针对DFI患者的精心设计的临床试验证据,并突出了需要基于未来试验制定管理指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/030a/5894166/9c36cbfdae74/13047_2018_256_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/030a/5894166/559488615876/13047_2018_256_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/030a/5894166/9c36cbfdae74/13047_2018_256_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/030a/5894166/559488615876/13047_2018_256_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/030a/5894166/9c36cbfdae74/13047_2018_256_Fig2_HTML.jpg

相似文献

1
Managing diabetic foot infections: a survey of Australasian infectious diseases clinicians.糖尿病足感染的管理:对澳大拉西亚传染病临床医生的一项调查。
J Foot Ankle Res. 2018 Apr 10;11:13. doi: 10.1186/s13047-018-0256-3. eCollection 2018.
2
Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors.糖尿病足感染的缓解:抗生素治疗的持续时间和其他可能的相关因素。
Diabetes Obes Metab. 2019 Feb;21(2):244-251. doi: 10.1111/dom.13507. Epub 2018 Sep 21.
3
Impact of dedicated infectious disease teamwork on the treatment and prognosis of patients with diabetic foot infection.传染病专业团队协作对糖尿病足感染患者治疗和预后的影响。
Int J Infect Dis. 2020 Nov;100:133-138. doi: 10.1016/j.ijid.2020.08.085. Epub 2020 Sep 9.
4
[Outpatient parenteral antibiotic therapy (OPAT) of diabetic foot infections with piperacillin/tazobactam].糖尿病足感染采用哌拉西林/他唑巴坦的门诊胃肠外抗生素治疗
Infez Med. 2002 Dec;10(4):230-5.
5
COVID-19 in the pre-pandemic period: a survey of the time commitment and perceptions of infectious diseases physicians in Australia and New Zealand.大流行前时期的 COVID-19:对澳大利亚和新西兰传染病医生的时间投入和认知的调查。
Intern Med J. 2020 Aug;50(8):924-930. doi: 10.1111/imj.14941.
6
Diabetic foot infections: what have we learned in the last 30 years?糖尿病足感染:过去30年我们学到了什么?
Int J Infect Dis. 2015 Nov;40:81-91. doi: 10.1016/j.ijid.2015.09.023. Epub 2015 Oct 13.
7
Oral amoxicillin-clavulanate for treating diabetic foot infections.口服阿莫西林-克拉维酸治疗糖尿病足感染。
Diabetes Obes Metab. 2019 Jun;21(6):1483-1486. doi: 10.1111/dom.13651. Epub 2019 Mar 12.
8
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.静脉/口服莫西沙星和静脉哌拉西林/他唑巴坦序贯口服阿莫西林/克拉维酸治疗糖尿病足感染的疗效和安全性:RELIEF 研究结果。
Infection. 2013 Feb;41(1):175-86. doi: 10.1007/s15010-012-0367-x. Epub 2012 Nov 23.
9
Correlation between superficial and intra-operative specimens in diabetic foot infections: results of a cross-sectional Tunisian study.
Afr Health Sci. 2019 Sep;19(3):2505-2514. doi: 10.4314/ahs.v19i3.26.
10
Opinions about the most appropriate surgical management of diabetes-related foot infection: a cross-sectional survey.关于糖尿病足感染最合适的手术治疗的意见:一项横断面调查。
J Foot Ankle Res. 2022 Mar 2;15(1):18. doi: 10.1186/s13047-022-00523-w.

引用本文的文献

1
Duration of antibiotherapy for patients with diabetic foot osteomyelitis without amputation: a protocol for a systematic review and network meta-analysis.非截肢糖尿病足骨髓炎患者的抗生素治疗疗程:一项系统评价和网状Meta分析方案
BMJ Open. 2025 Jun 5;15(6):e093342. doi: 10.1136/bmjopen-2024-093342.
2
Foot, ankle, and leg problems in Australian primary care: consultation patterns, management practices, and costs.澳大利亚初级保健中的足部、踝关节和腿部问题:咨询模式、管理实践和费用。
Fam Pract. 2024 Aug 14;41(4):426-433. doi: 10.1093/fampra/cmac122.
3
Opinions about the most appropriate surgical management of diabetes-related foot infection: a cross-sectional survey.

本文引用的文献

1
Direct inpatient burden caused by foot-related conditions: a multisite point-prevalence study.足部相关疾病导致的直接住院负担:一项多地点现患率研究。
BMJ Open. 2016 Jun 20;6(6):e010811. doi: 10.1136/bmjopen-2015-010811.
2
Prevalence of foot disease and risk factors in general inpatient populations: a systematic review and meta-analysis.普通住院患者足部疾病的患病率及危险因素:一项系统评价和荟萃分析。
BMJ Open. 2015 Nov 23;5(11):e008544. doi: 10.1136/bmjopen-2015-008544.
3
High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE study).
关于糖尿病足感染最合适的手术治疗的意见:一项横断面调查。
J Foot Ankle Res. 2022 Mar 2;15(1):18. doi: 10.1186/s13047-022-00523-w.
4
Establishing the national top 10 priority research questions to improve diabetes-related foot health and disease: a Delphi study of Australian stakeholders.确立全国十大优先研究问题以改善糖尿病相关足部健康和疾病:澳大利亚利益相关者的德尔菲研究。
BMJ Open Diabetes Res Care. 2021 Nov;9(2). doi: 10.1136/bmjdrc-2021-002570.
5
Availability and service provision of multidisciplinary diabetes foot units in Australia: a cross-sectional survey.澳大利亚多学科糖尿病足单位的服务提供情况:一项横断面调查。
J Foot Ankle Res. 2021 Apr 7;14(1):27. doi: 10.1186/s13047-021-00471-x.
6
Clinical, Pathological and Microbiological Evaluation of Diabetic Foot Syndrome.糖尿病足综合征的临床、病理和微生物学评估。
Medicina (Kaunas). 2020 Jul 28;56(8):380. doi: 10.3390/medicina56080380.
7
Oral Flucloxacillin for Treating Osteomyelitis: A Narrative Review of Clinical Practice.口服氟氯西林治疗骨髓炎:临床实践的叙述性综述
J Bone Jt Infect. 2020 Jan 1;5(1):16-24. doi: 10.7150/jbji.40667. eCollection 2020.
8
Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives.糖尿病足溃疡的细菌多样性:现状与未来展望
J Clin Med. 2019 Nov 10;8(11):1935. doi: 10.3390/jcm8111935.
澳大利亚北部地区糖尿病足感染负担沉重:一场新出现的健康危机(DEFINE研究)。
Diabetes Res Clin Pract. 2015 Nov;110(2):147-57. doi: 10.1016/j.diabres.2015.09.016. Epub 2015 Sep 21.
4
IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes.国际糖尿病足工作组关于糖尿病患者足部感染诊断与管理的指南。
Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:45-74. doi: 10.1002/dmrr.2699.
5
Interventions in the management of infection in the foot in diabetes: a systematic review.糖尿病足感染管理中的干预措施:系统评价。
Diabetes Metab Res Rev. 2016 Jan;32 Suppl 1:145-53. doi: 10.1002/dmrr.2706.
6
Reduced Incidence of Foot-Related Hospitalisation and Amputation amongst Persons with Diabetes in Queensland, Australia.澳大利亚昆士兰州糖尿病患者足部相关住院和截肢发生率降低
PLoS One. 2015 Jun 22;10(6):e0130609. doi: 10.1371/journal.pone.0130609. eCollection 2015.
7
Outcomes and cost minimisation associated with outpatient parenteral antimicrobial therapy (OPAT) for foot infections in people with diabetes.糖尿病患者足部感染门诊胃肠外抗菌治疗(OPAT)的治疗效果及成本最小化
Diabetes Metab Res Rev. 2015 Sep;31(6):638-45. doi: 10.1002/dmrr.2651. Epub 2015 May 19.
8
Temporal changes in the prevalence and associates of foot ulceration in type 2 diabetes: the Fremantle Diabetes Study.2型糖尿病患者足部溃疡患病率及相关因素的时间变化:弗里曼特尔糖尿病研究
J Diabetes Complications. 2015 Apr;29(3):356-61. doi: 10.1016/j.jdiacomp.2015.01.008. Epub 2015 Jan 19.
9
What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore.传染病医师的工作内容是什么?对澳大利亚、新西兰和新加坡的住院会诊活动进行为期两周的快照分析。
Clin Microbiol Infect. 2014 Oct;20(10):O737-44. doi: 10.1111/1469-0691.12581. Epub 2014 Mar 6.
10
Determining research priorities for clinician-initiated trials in infectious diseases.确定传染病领域临床医生主导试验的研究重点。
Med J Aust. 2013 Mar 18;198(5):270-2. doi: 10.5694/mja12.11703.